Creative Planning Buys 4,906 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Creative Planning lifted its position in Exact Sciences Co. (NASDAQ:EXAS) by 14.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,060 shares of the medical research company’s stock after buying an additional 4,906 shares during the quarter. Creative Planning’s holdings in Exact Sciences were worth $2,593,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brookstone Capital Management bought a new position in shares of Exact Sciences in the 1st quarter valued at about $387,000. Wealth Enhancement Advisory Services LLC grew its holdings in Exact Sciences by 1.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 35,809 shares of the medical research company’s stock worth $2,473,000 after purchasing an additional 498 shares during the period. SteelPeak Wealth LLC acquired a new position in Exact Sciences during the first quarter worth approximately $287,000. Diversified Trust Co raised its stake in Exact Sciences by 138.0% in the first quarter. Diversified Trust Co now owns 9,980 shares of the medical research company’s stock valued at $689,000 after buying an additional 5,786 shares during the period. Finally, Wasatch Advisors LP lifted its position in shares of Exact Sciences by 14.4% in the first quarter. Wasatch Advisors LP now owns 299,248 shares of the medical research company’s stock valued at $20,666,000 after buying an additional 37,668 shares during the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

EXAS has been the topic of a number of recent analyst reports. Evercore ISI boosted their target price on Exact Sciences from $72.00 to $80.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Stifel Nicolaus dropped their price objective on shares of Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Benchmark reduced their target price on shares of Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 1st. Raymond James reissued a “market perform” rating on shares of Exact Sciences in a report on Thursday, September 26th. Finally, Piper Sandler boosted their price objective on Exact Sciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a report on Thursday, September 12th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.38.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $69.11 on Friday. The business has a fifty day moving average price of $65.77 and a two-hundred day moving average price of $56.58. The company has a quick ratio of 1.98, a current ratio of 2.17 and a debt-to-equity ratio of 0.73. Exact Sciences Co. has a fifty-two week low of $40.62 and a fifty-two week high of $79.62.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.28. The business had revenue of $699.26 million during the quarter, compared to the consensus estimate of $690.02 million. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. Exact Sciences’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.45) earnings per share. On average, equities research analysts anticipate that Exact Sciences Co. will post -0.87 EPS for the current year.

Insider Transactions at Exact Sciences

In other Exact Sciences news, EVP Brian Baranick sold 929 shares of the firm’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the sale, the executive vice president now owns 12,758 shares of the company’s stock, valued at approximately $893,060. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.36% of the stock is currently owned by insiders.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.